Insight Molecular Enrolls First Patients in GALACTIC Study

The prospective registry validates GraftAssure, a molecular test for monitoring kidney transplant rejection, with patient samples arriving from UCLA Medical Center in Tennessee.

Updated on Nov. 20, 2026 in Tech

Isometric editorial illustration of plain glass sample vials in a rack on a laboratory bench beside a centrifuge, in cream, slate blue, and teal, evoking a diagnostic validation study.
Insight Molecular Diagnostics has enrolled its first patients in the GALACTIC registry, which will test whether its GraftAssure kidney-rejection monitoring test can exceed 80% positive predictive value. AI Illustration. Upload story photo >

Insight Molecular Diagnostics has enrolled its first several patients in the GALACTIC registry, a prospective, multi-center validation study of GraftAssure, a molecular test for monitoring rejection in kidney transplant recipients. Patient samples arrived from UCLA Medical Center in Tennessee.

Why it matters

The registry targets 5,000 participants and aims to show a positive predictive value above 80%, compared with roughly 50% for current assays. Data from the study is expected to inform payer coverage decisions for products using GraftAssure technology.

A June 2026 study in the American Journal of Transplantation reported an 81% positive predictive value for the CM-Score, compared with a published 54% benchmark for single-metric donor-derived cell-free DNA testing. Whether the GALACTIC registry will confirm this performance across its 5,000 target participants will not be known until the planned follow-up of about three years is complete.

The players

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics is the company that runs the GALACTIC registry and develops the GraftAssure transplant rejection tests.

UCLA Medical Center

UCLA Medical Center is a major academic hospital in Los Angeles that is participating in the GALACTIC registry study and enrolled its first patient.

The details

The CM-score mathematically combines the relative percentage and absolute copies-per-milliliter measurements of DNA fragments from the transplanted kidney. The observational study builds evidence supporting the previously published Combination Model (CM)-Score, first presented at the World Transplant Congress in August 2025.

Timeline

  1. August 2025: CM-score data first presented at World Transplant Congress.

  2. September 2025: GALACTIC registry first announced.

  3. June 2026: Peer-reviewed CM-Score study published in American Journal of Transplantation.

  4. November 20, 2026: First patient samples arrived and registry enrollment announced.

  5. About three years after enrollment: Planned study follow-up period concludes.

Roadmap

The GALACTIC registry extends the previously published Combination Model (CM)-Score from earlier validation work into a prospective, multi-center setting. It positions donor-derived cell-free DNA monitoring as a candidate for broader payer coverage in kidney transplant care.

For kidney transplant recipients, a more accurate rejection test could mean fewer unnecessary biopsies and earlier detection of problems. If validated, these tests may also influence whether insurers cover the testing that patients and clinicians rely on.

The takeaway

Accurate, noninvasive rejection monitoring could change how transplant patients are followed over time. The outcome of the registry will show whether the 81% predictive value holds up in real-world enrollment.

What happens next

Insight Molecular expects the GALACTIC registry to run for about three years of follow-up, with data expected to inform payer coverage decisions along the way.

Further reading

Explore more Biotech developments shaping transplant diagnostics and medical testing.

Source note: This article includes information reported by The Manila times.